{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:05:32Z","timestamp":1789477532115,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"DOI":"10.1038\/s41416-026-03528-5","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:58:20Z","timestamp":1783090700000},"page":"1045-1050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The concept of functional cure in advanced\/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone"],"prefix":"10.1038","volume":"135","author":[{"given":"Ana","family":"Cavillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-4730","authenticated-orcid":false,"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-4679","authenticated-orcid":false,"given":"Raphael","family":"Porcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-0659","authenticated-orcid":false,"given":"Thomas","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"3528_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998\u20131012.","journal-title":"N Engl J Med"},{"key":"3528_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392:11\u201322.","journal-title":"N Engl J Med"},{"key":"3528_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392.","journal-title":"Lancet Oncol"},{"key":"3528_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"3528_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"key":"3528_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. JCO. 2022;40:127\u201337.","journal-title":"JCO"},{"key":"3528_CR7","doi-asserted-by":"publisher","first-page":"e438654","DOI":"10.1200\/EDBK_438654","volume":"44","author":"PY Chan","year":"2024","unstructured":"Chan PY, Corrie PG. Curing Stage IV melanoma: where have we been and where are we? Am Soc Clin Oncol Educ Book. 2024;44:e438654.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3528_CR8","doi-asserted-by":"publisher","first-page":"e2139573","DOI":"10.1001\/jamanetworkopen.2021.39573","volume":"4","author":"T Filleron","year":"2021","unstructured":"Filleron T, Bachelier M, Mazieres J, et al. Assessment of treatment effects and long-term benefits in immune checkpoint inhibitor trials using the flexible parametric cure model: a systematic review. JAMA Netw Open. 2021;4:e2139573.","journal-title":"JAMA Netw Open"},{"key":"3528_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jamaoncol.2019.2186","volume":"5","author":"S Zimmermann","year":"2019","unstructured":"Zimmermann S, Peters S. Appraising the Tail of the Survival Curve in the Era of PD-1\/PD-L1 Checkpoint Blockade. JAMA Oncol. 2019;5:1403\u20135.","journal-title":"JAMA Oncol"},{"key":"3528_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/865101","volume":"2015","author":"P Johnson","year":"2015","unstructured":"Johnson P, Greiner W, Al-Dakkak I, Wagner S. Which metrics are appropriate to describe the value of new cancer therapies?. Biomed Res Int. 2015;2015:865101.","journal-title":"Biomed Res Int"},{"key":"3528_CR11","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1182\/blood.2021012854","volume":"138","author":"M Mohty","year":"2021","unstructured":"Mohty M, Avet-Loiseau H, Harousseau JL. Requirements for operational cure in multiple myeloma. Blood. 2021;138:1406\u201311.","journal-title":"Blood"},{"key":"3528_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-00946-8","volume":"20","author":"LH Jakobsen","year":"2020","unstructured":"Jakobsen LH, Andersson TML, Biccler JL, et al. On estimating the time to statistical cure. BMC Med Res Methodol. 2020;20:71.","journal-title":"BMC Med Res Methodol"},{"key":"3528_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1088\/0031-9155\/49\/6\/015","volume":"49","author":"RF Mould","year":"2004","unstructured":"Mould RF, Asselain B, Rycke YD. Methodology to predict a maximum follow-up period for breast cancer patients without significantly reducing the chance of detecting a local recurrence. Phys Med Biol. 2004;49:1079\u201383.","journal-title":"Phys Med Biol"},{"key":"3528_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-96","volume":"11","author":"TM Andersson","year":"2011","unstructured":"Andersson TM, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011;11:96.","journal-title":"BMC Med Res Methodol"},{"key":"3528_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canep.2018.01.013","volume":"53","author":"O Boussari","year":"2018","unstructured":"Boussari O, Romain G, Remontet L, et al. A new approach to estimate time-to-cure from cancer registries data. Cancer Epidemiol. 2018;53:72\u201380.","journal-title":"Cancer Epidemiol"},{"key":"3528_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-1","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:1.","journal-title":"BMC Med Res Methodol"},{"key":"3528_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/1078-0432.CCR-11-2859","volume":"18","author":"M Othus","year":"2012","unstructured":"Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18:14.","journal-title":"Clin Cancer Res"},{"key":"3528_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.eururo.2023.02.011","volume":"85","author":"A Cavillon","year":"2024","unstructured":"Cavillon A, Pouessel D, Hou\u00e9d\u00e9 N, et al. Assessing long-term treatment benefits using complementary statistical approaches: an in silico analysis of the phase III keynote-045 and checkmate-214 immune checkpoint inhibitor trials. Eur Urol. 2024;85:293\u2013300.","journal-title":"Eur Urol"},{"key":"3528_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/sj.bjc.6604466","volume":"99","author":"A Shah","year":"2008","unstructured":"Shah A, Stiller CA, Kenward MG, Vincent T, Eden TOB, Coleman MP. Childhood leukaemia: long-term excess mortality and the proportion \u201ccured. Br J Cancer. 2008;99:219\u201323.","journal-title":"Br J Cancer"},{"key":"3528_CR20","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jamaoncol.2025.3760","volume":"11","author":"A Pastorino","year":"2025","unstructured":"Pastorino A, Liu H, Pederson L, et al. The definition of cure in colon cancer: a pooled analysis of 15 randomized clinical trials. JAMA Oncol. 2025;11:1440\u20138.","journal-title":"JAMA Oncol"},{"key":"3528_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1536867X0900900206","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J: Promoting Commun Stat Stata. 2009;9:265\u201390.","journal-title":"Stata J: Promoting Commun Stat Stata"},{"key":"3528_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jval.2022.07.009","volume":"26","author":"S Palmer","year":"2023","unstructured":"Palmer S, Borget I, Friede T, et al. A guide to selecting flexible survival models to inform economic evaluations of cancer immunotherapies. Value Health. 2023;26:185\u201392.","journal-title":"Value Health"},{"key":"3528_CR23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686\u20139.","journal-title":"Lancet"},{"key":"3528_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/ije\/dyy013","volume":"47","author":"V Gebski","year":"2018","unstructured":"Gebski V, Gar\u00e8s V, Gibbs E, Byth K. Data maturity and follow-up in time-to-event analyses. Int J Epidemiol. 2018;47:850\u20139.","journal-title":"Int J Epidemiol"},{"key":"3528_CR25","first-page":"260","volume":"75","author":"SJ Mitchell","year":"2004","unstructured":"Mitchell SJ, Evans AD. Flight safety and medical incapacitation risk of airline pilots. Aviat Space Environ Med. 2004;75:260\u20138.","journal-title":"Aviat Space Environ Med"},{"key":"3528_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.clgc.2016.07.023","volume":"15","author":"SMA Somda","year":"2017","unstructured":"Somda SMA, Culine S, Chevreau C, et al. A statistical approach to determine the optimal duration of post-treatment follow-up: application to metastatic nonseminomatous germ cell tumors. Clin Genitourin Cancer. 2017;15:230\u20136.","journal-title":"Clin Genitourin Cancer"},{"key":"3528_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/sim.987","volume":"21","author":"R Sposto","year":"2002","unstructured":"Sposto R. Cure model analysis in cancer: an application to data from the Children\u2019s Cancer Group. Stat Med. 2002;21:293\u2013312.","journal-title":"Stat Med"},{"key":"3528_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/(SICI)1097-0258(19990228)18:4<441::AID-SIM23>3.0.CO;2-M","volume":"18","author":"R De Angelis","year":"1999","unstructured":"De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med. 1999;18:441\u201354.","journal-title":"Stat Med"},{"key":"3528_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.24.00237","volume":"43","author":"JS Weber","year":"2025","unstructured":"Weber JS, Middleton MR, Yates G, et al. Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III\/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials. J Clin Oncol. 2025;43:929\u201337.","journal-title":"J Clin Oncol"},{"key":"3528_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41416-025-03264-2","volume":"134","author":"L Mateos","year":"2026","unstructured":"Mateos L, Jim\u00e9nez-Fonseca P, Gallego J, et al. Does perioperative FLOT increase cure rates in resectable esophageal adenocarcinoma? A mixture cure model analysis. Br J Cancer. 2026;134:414\u201327.","journal-title":"Br J Cancer"},{"key":"3528_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.2517-6161.1949.tb00020.x","volume":"11","author":"JW Boag","year":"1949","unstructured":"Boag JW. Maximum Likelihood Estimates of the Proportion of Patients Cured by Cancer Therapy. J R Stat Soc Ser B: Stat Methodol. 1949;11:15\u201344.","journal-title":"J R Stat Soc Ser B: Stat Methodol"},{"key":"3528_CR32","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1789::AID-CNCR20>3.0.CO;2-Q","volume":"85","author":"AY Yakovlev","year":"1999","unstructured":"Yakovlev AY, Tsodikov AD, Boucher K, Kerber R. The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer. 1999;85:1789\u201398.","journal-title":"Cancer"},{"key":"3528_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1177\/1536867X1201200404","volume":"12","author":"TML Andersson","year":"2012","unstructured":"Andersson TML, Lambert PC. Fitting and Modeling Cure in Population-Based Cancer Studies within the Framework of Flexible Parametric Survival Models. Stata J: Promoting Commun Stat Stata. 2012;12:623\u201338.","journal-title":"Stata J: Promoting Commun Stat Stata"},{"key":"3528_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2015.64.2488","volume":"34","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. J Clin Oncol. 2016;34:15.","journal-title":"J Clin Oncol"},{"key":"3528_CR35","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","volume":"37","author":"MJNM Ouwens","year":"2019","unstructured":"Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. PharmacoEconomics. 2019;37:1129\u201338.","journal-title":"PharmacoEconomics"},{"key":"3528_CR36","doi-asserted-by":"publisher","first-page":"djv366","DOI":"10.1093\/jnci\/djv366","volume":"108","author":"NA De Glas","year":"2016","unstructured":"De Glas NA, Kiderlen M, Vandenbroucke JP, et al. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. JNCIJ. 2016;108:djv366.","journal-title":"JNCIJ"},{"key":"3528_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/1536867X1701700212","volume":"17","author":"SI Mozumder","year":"2017","unstructured":"Mozumder SI, Rutherford MJ, Lambert PC. A Flexible Parametric Competing-risks Model Using a Direct Likelihood Approach for the Cause-specific Cumulative Incidence Function. Stata J. 2017;17:2.","journal-title":"Stata J"},{"key":"3528_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/0272989X20978958","volume":"41","author":"J Gray","year":"2021","unstructured":"Gray J, Sullivan T, Latimer NR, et al. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer. Med Decis Mak. 2021;41:179\u201393.","journal-title":"Med Decis Mak"},{"key":"3528_CR39","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","volume":"31","author":"U Keilholz","year":"2020","unstructured":"Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435\u201348.","journal-title":"Ann Oncol"},{"key":"3528_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08509-w","volume":"21","author":"O Coen","year":"2021","unstructured":"Coen O, Corrie P, Marshall H, et al. The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer. 2021;21:761.","journal-title":"BMC Cancer"},{"key":"3528_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08018-w","volume":"21","author":"EEAP Mulder","year":"2021","unstructured":"Mulder EEAP, De Joode K, Liti\u00e8re S, et al. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. BMC Cancer. 2021;21:323.","journal-title":"BMC Cancer"},{"key":"3528_CR42","doi-asserted-by":"crossref","unstructured":"LeBlanc TW, Temel JS, Helft PR \u201cHow Much Time Do I Have?\u201d: Communicating Prognosis in the Era of Exceptional Responders. Am Soc Clin Oncol Educ Book. 2018 787-94.","DOI":"10.1200\/EDBK_201211"},{"key":"3528_CR43","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1007\/s00520-020-05846-7","volume":"29","author":"A Malmstr\u00f6m","year":"2021","unstructured":"Malmstr\u00f6m A, \u00c5kesson L, Milos P, et al. Do I want to know it all?\u201d A qualitative study of glioma patients\u2019 perspectives on receiving information about their diagnosis and prognosis. Support Care Cancer. 2021;29:3339\u201346.","journal-title":"Support Care Cancer"},{"key":"3528_CR44","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1200\/JCO.22.02212","volume":"41","author":"J Lai-Kwon","year":"2023","unstructured":"Lai-Kwon J, Heynemann S, Hart NH, et al. Evolving Landscape of Metastatic Cancer Survivorship: Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era. J Clin Oncol. 2023;41:3304\u201310.","journal-title":"J Clin Oncol"},{"key":"3528_CR45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jnci\/djab223","volume":"114","author":"MA Mollica","year":"2022","unstructured":"Mollica MA, Smith AW, Tonorezos E, et al. Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report. J Natl Cancer Inst. 2022;114:489\u201395.","journal-title":"J Natl Cancer Inst"},{"key":"3528_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471752","volume":"45","author":"M Jefford","year":"2025","unstructured":"Jefford M, Nekhlyudov L, Smith AL, Chan RJ, Lai-Kwon J, Hart NH. Survivorship Care for People Affected by Advanced or Metastatic Cancer: Building on the Recent Multinational Association of Supportive Care in Cancer-ASCO Standards and Practice Recommendations. Am Soc Clin Oncol Educ Book. 2025;45:e471752.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3528_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2005.09.012","volume":"78","author":"OU Ataman","year":"2006","unstructured":"Ataman OU, Barrett A, Filleron T, Kramar A, ESTRO-REACT Group. Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO. Radiother Oncol. 2006;78:95\u2013100.","journal-title":"Radiother Oncol"},{"key":"3528_CR48","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0272989X08327331","volume":"29","author":"T Filleron","year":"2009","unstructured":"Filleron T, Barrett A, Ataman O, Kramar A. Planning posttherapeutic oncology surveillance visits based on individual risk. Med Decis Mak. 2009;29:570\u20139.","journal-title":"Med Decis Mak"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03528-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03528-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:13:54Z","timestamp":1789474434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03528-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3528"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03528-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ana Cavillon, None. Isabelle Borget Outside the submitted work: BMS, Roche, Gilead, Janssen, MSD, Novartis. Caroline Robert Consultant Advisory Board: Pierre Fabre, BMS, MSD, Merck, Roche, Pfizer, Sun Pharma, Regeneron, Maat Pharma, Iovance, Moderna, Immatics outside the submitted work, Consultant Steering Committee: Regeneron, Pfizer, IO Biotech outside the submitted work. Speaker: Pierre Fabre, BMS, MSD, Novartis outside the submitted work. Travel: Pierre Fabre outside the submitted work. Sylvie Chevret None. Jean-Pierre Delord institutional fees from BMS, Merck Serono, MSD, Pierre Fabre, Roche outside the submitted work; research grant from Amgen, AstraZeneca, BMS, Genentech, MSD, Transgene outside the submitted work. Raphael Porcher None. Thomas Filleron Personal fees from Jansen, Biogen and Pfizer outside the submitted work; institutional fees from Roche, Lilly outside the submitted work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}